The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
Official Title: An Open-label, Single-arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AUY922 in Combination With Trastuzumab Standard Therapy as Second-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
Study ID: NCT01402401
Brief Summary: This study will assess the safety and efficacy of AUY922, when administered, in combination with trastuzumab in adult patients with HER2+ advanced gastric cancer, who have received trastuzumab plus chemotherapy in the first line.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of California at Los Angeles UCLA LeConte Location, Los Angeles, California, United States
Clinical Research Alliance, Lake Success, New York, United States
University of Texas/MD Anderson Cancer Center UT SC, Houston, Texas, United States
Novartis Investigative Site, Leuven, , Belgium
Novartis Investigative Site, Bordeaux Cedex, , France
Novartis Investigative Site, Nice Cedex 2, , France
Novartis Investigative Site, Reims, , France
Novartis Investigative Site, Mannheim, Baden-Württemberg, Germany
Novartis Investigative Site, Heilbronn, , Germany
Novartis Investigative Site, Modena, MO, Italy
Novartis Investigative Site, Kashiwa, Chiba, Japan
Novartis Investigative Site, Sapporo-city, Hokkaido, Japan
Novartis Investigative Site, Seoul, Korea, Korea, Republic of
Novartis Investigative Site, Seoul, Korea, Korea, Republic of
Novartis Investigative Site, Barcelona, Cataluña, Spain
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR